Carotid versus femoral access for transcatheter aortic valve implantation: a propensity score inverse probability weighting study.


Journal

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
ISSN: 1873-734X
Titre abrégé: Eur J Cardiothorac Surg
Pays: Germany
ID NLM: 8804069

Informations de publication

Date de publication:
01 Dec 2019
Historique:
received: 17 01 2019
revised: 22 06 2019
accepted: 25 06 2019
pubmed: 1 8 2019
medline: 18 11 2020
entrez: 1 8 2019
Statut: ppublish

Résumé

The transcarotid (TC) approach for transcatheter aortic valve implantation (TAVI) is potentially an optimal alternative to the transfemoral (TF) approach. Our goal was to compare the safety and efficacy of TC- and TF-TAVI. Patients who underwent TF-TAVI or TC-TAVI in the prospectively collected FRANCE TAVI registry between January 2013 and December 2015 were compared. Propensity score inverse probability weighting methods were employed to minimize the impact of bias related to non-random treatment assignment. Of the 11 033 patients included in the current study, 10 598 (96%) underwent a TF-TAVI and 435 (4.1%) had a TC-TAVI. Patients in the TC-TAVI access group presented with a higher risk profile but were significantly younger. There were no differences in the perioperative and 2-year mortality rates after adjustment [odds ratio (OR) 1.02, 95% confidence interval (CI) 0.62-1.68; P = 0.99 and hazard ratio 1.03, 95% CI 0.7-1.35; P = 0.83). TC-TAVI was associated with a significant risk of stroke (OR 2.42, 95% CI 2.01-2.92; P < 0.001), ST-elevation myocardial infarction (OR 7.32, 95% CI 3.87-13.87; P < 0.001), infections (OR 2.36, 95% CI 2.04-2.71; P < 0.001), bleeding (OR 2.01, 95% CI 1.76-2.29; P < 0.001), renal failure (OR 2.23, 95% CI 1.90-2.60; P < 0.001) and need for dialysis (OR 2.36, 95% CI 2.01-2.76, P < 0.001). Conversely, TC-TAVI was not confirmed as a risk factor for pacemaker implantation after adjustment (OR 1.05, 95% CI 0.96-1.15; P < 0.28) and was a protective factor for vascular complications (OR 0.37, 95% CI 0.32-0.43; P < 0.001). TC-TAVI is a safe procedure compared to TF-TAVI, although it holds an increased risk of perioperative complications. It should be considered in case of non-femoral peripheral access as the second access choice, to increase the overall safety of TAVI procedures.

Identifiants

pubmed: 31365061
pii: 5542047
doi: 10.1093/ejcts/ezz216
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1140-1146

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Auteurs

Thierry A Folliguet (TA)

Department of Cardiac Surgery and Cardiology, Assistance Publique-Hôpitaux de Paris, Hospital Henri Mondor, University Paris 12 UPEC, Creteil, France.

Emmanuel Teiger (E)

Department of Cardiac Surgery and Cardiology, Assistance Publique-Hôpitaux de Paris, Hospital Henri Mondor, University Paris 12 UPEC, Creteil, France.

Sylvain Beurtheret (S)

Cardiac Surgery Department, Saint Joseph Hospital, Marseille, France.

Thomas Modine (T)

Cardiac Surgery Department, Cardiologic University Hospital, Lille, France.

Thierry Lefevre (T)

Paris South Cardio-vascular Institute, Jacques-Cartier Private Hospital, Massy, France.

Eric Van Belle (E)

Department of Cardiology, University of Lille 2, Regional University Hospital Center of Lille, National Institute of Health and Medical Research U1011, University Hospital Federation Integra, Lille, France.

Martine Gilard (M)

Department of Cardiology, La Cavale Blanche University Hospital Center, Optimization of Physiological Regulations, Science and Technical Training and Research Unit, University of Western Brittany, Brest, France.

Helene Eltchaninoff (H)

Cardiology Service, Rouen-Charles-Nicolle University Hospital Center, National Institute of Health and Medical Research U644, Rouen, France.

René Koning (R)

Cardiology Service, Saint Hilaire Clinic, Rouen, France.

Bernard Iung (B)

Department of Cardiology, University Hospital Department and Paris-Diderot University, Public Assistance Hospitals of Paris, Bichat Hospital, Paris, France.

Jean Philippe Verhoye (JP)

Thoracic and Cardiovascular Surgery Service, Pontchaillou University Hospital Center, University of Rennes 1, Signal and Image Treatment Laboratory (LTSI), National Institute of Health and Medical Research U1099, Rennes, France.

Pascal Leprince (P)

Cardiac Surgery Department, Sorbonne-Pierre-et-Marie-Curie University, Public Assistance Hospitals of Paris, Groupe Hospitalier de la Pitié Salpêtrière (GHPS), Paris, France.

Hervé Le Breton (H)

Cardiology and Vascular Diseases Service, Pontchaillou University Hospital Center, Center for Clinical Investigation 804, University of Rennes 1, Signal and Image Treatment Laboratory (LTSI), National Institute of Health and Medical Research U1099, Rennes, France.

Antoine Lafont (A)

Paris Cardiovascular Research Center, INSERM Unit 970, Paris, France.
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France.

Alessandro Parolari (A)

Universitary Cardiac Surgery, Policlinico S. Donato IRCCS, University of Milan, Milan, Italy.

Fabio Barili (F)

Department of Cardiovascular Surgery, S. Croce Hospital, Cuneo, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH